A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

We compared disease-modifying antirheumatic drug (DMARD) use for older adults with rheumatoid arthritis (RA)-related ambulatory visits from rheumatologists and primary care providers (PCPs). We ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

Please provide your email address to receive an email when new articles are posted on . Nearly all bDMARDs and tsDMARDs feature infection or malignancy warnings from the FDA or European Medicines ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost management strategies.

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...

Researchers conducted an open-label randomised trial including 65 adults with active RA (mean age, 59.1 years; median disease duration, 13 years) across seven hospitals in Netherlands between February ...

Traditional medications are synthesized through chemical reactions, whereas biologics are derived from and reproduced, at least partially, from living organisms. For instance, blood and plasma ...